The global acute myeloid leukemia (AML) therapeutics market is set to expand significantly, with projections indicating growth from USD 3.8 billion in 2025 to USD 10.1 billion by 2036, according to a new report from Fact.MR. This represents a compound annual growth rate (CAGR) of 9.2% over the forecast period, creating an absolute dollar opportunity of approximately USD 5.9 billion. The market's expansion reflects a fundamental shift in treatment paradigms, moving from traditional chemotherapy toward genomics-driven, targeted therapies and personalized medicine approaches.
Targeted therapies are expected to become the leading drug class, capturing 36% of market share in 2026. These therapies, which target specific genetic mutations such as FLT3 and NPM1, offer improved efficacy and reduced toxicity compared to conventional treatments. The increasing availability of mutation-specific drugs is expanding options for patients with genetically defined AML subtypes, enabling more personalized care strategies. Hospitals remain the primary end-user, accounting for 55% of market demand, due to the intensive nature of AML treatment, which often requires inpatient management, blood transfusion support, and continuous monitoring. Hospital pharmacies also hold a dominant position with 49% market share, reflecting the complexity of AML therapies and the need for specialized handling and administration.
Newly diagnosed AML represents the largest patient segment, holding 48% market share in 2026, as initial treatment regimens generate the highest therapy volumes. Growing awareness, improved diagnostics, and wider access to oncology services are driving treatment initiation rates globally. However, one of the strongest growth drivers is the increasing availability of therapies for relapsed and refractory AML. New oral targeted therapies, menin inhibitors, and mutation-specific treatments are providing options for patients who previously had limited alternatives. Recent regulatory approvals and clinical advancements continue to strengthen the treatment landscape, offering hope for difficult-to-treat cases.
Regional markets show strong growth potential, with South Asia and East Asia emerging as high-growth regions due to expanding cancer care infrastructure and increasing access to molecular diagnostics. Among key countries, India is projected to grow at 11.8% CAGR, China at 10.9%, the United States at 8.7%, Germany at 7.9%, and Japan at 7.4%. North America continues to lead in revenue due to strong specialty pharmacy networks and high healthcare spending, while Western Europe remains supported by advanced hematology care centers and established reimbursement frameworks.
The competitive landscape features major pharmaceutical companies such as AbbVie Inc., Genentech (Roche), Astellas Pharma Inc., Syndax Pharmaceuticals, Inc., and Kura Oncology, Inc. These industry participants are investing heavily in precision medicine, molecular diagnostics partnerships, clinical trials, and patient access programs to strengthen their positioning. According to Shambhu Nath Jha, Principal Consultant at Fact.MR, the future of AML treatment will increasingly depend on molecular testing, precision treatment selection, and therapies that balance efficacy with improved tolerability for diverse patient populations. Despite challenges related to treatment costs and reimbursement constraints, the long-term outlook remains positive as innovation continues to reshape the global hematology treatment landscape.
